Skip to main content
SpringerLink
Log in

Pathology of Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 357 Accesses

Abstract

Treatment for patients with advanced non-small cell lung cancer (NSCLC) has expanded to include histology-based chemotherapy, targeted therapy, and immunotherapy in the past two decades along with the rapidly advanced molecular diagnostic testing. As such, accurate subtyping of lung carcinomas has become of paramount importance for appropriate patient management. In addition, a systematic approach to histologic classification of lung adenocarcinoma has been implemented in the past decade and is proven to stratify patient outcomes after resection. Thus, in this chapter, histologic classification of adenocarcinoma will be discussed in detail, along with a brief discussion of squamous cell carcinoma histology including the differentiation from adenocarcinoma and other histologic types in morphologically undifferentiated tumors in particular. A few other histologic types that are pertinent to therapeutic decision-making will also be described, and a multimodality approach for a comprehensive diagnosis of advanced NSCLC including predictive biomarker testing will be discussed. Finally, given that the scope of this publication is radiation oncology, the chapter will end with a discussion on pathology assessment of post-neoadjuvant resections for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alexander M, Galeas J, Cheng H (2018) Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell? J Thorac Dis 10(Suppl 33):S3994–S3998

    Google Scholar 

  • Amer W, Toth C, Vassella E, Meinrath J, Koitzsch U, Arens A et al (2017) Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome. Sci Rep 7(1):11069

    Google Scholar 

  • Amin M, Byrd D, Edge S, Green F (eds) (2017) AJCC cancer staging manual, 8th edn. Springer, New York

    Google Scholar 

  • Beasley MB, Lantuejoul S, Abbondanzo S, Chu WS, Hasleton PS, Travis WD et al (2003) The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 34(2):136–142

    Google Scholar 

  • Bishop JA, Ogawa T, Chang X, Illei PB, Gabrielson E, Pai SI et al (2012) HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol 36(1):142–148

    Google Scholar 

  • Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV et al (2018) Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol 13(12):1818–1831

    Google Scholar 

  • Brambilla E, Moro D, Veale D, Brichon PY, Stoebner P, Paramelle B et al (1992) Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol 23(9):993–1003

    Google Scholar 

  • Brambilla E, Lantuejoul S, Butnor KJ, Caporaso NE, Chen G, Chou TY et al (2015a) Basaloid squamous cell carcinoma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (eds) WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon, France, pp 56–58

    Google Scholar 

  • Brambilla E, Beasley MB, Austin JHM, Capelozzi VL, Chirieac LR, Devesa SS et al (2015b) Small cell carcinoma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (eds) WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon, France, pp 63–68

    Google Scholar 

  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ et al (2012) The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 7(12):1767–1774

    Google Scholar 

  • Cardesa A, Gal A, Nadal A (2005) Squamous cell carcinoma. In: Barnes L, Eveson JW, Reichart P (eds) WHO classification of tumours: head and neck tumours. IARC Press, Lyon, France, pp 118–121

    Google Scholar 

  • Chan JKC, Bray F, McCarron PF (2005) Nasopharyngeal carcinoma. In: Barnes L, Eveson JW, Reichart P (eds) WHO classification of tumours: head and neck tumours. Lyon, France, IARC Press, pp 85–97

    Google Scholar 

  • Chang SY, Keeney M, Law M, Donovan J, Aubry MC, Garcia J (2015) Detection of human papillomavirus in non-small cell carcinoma of the lung. Hum Pathol 46(11):1592–1597

    Google Scholar 

  • Chang JC, Alex D, Bott M, Tan KS, Seshan V, Golden A et al (2019) Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic approach. Clin Cancer Res 25(23):7113–7125

    Google Scholar 

  • Choi SE, Hong SW, Yoon SO (2015) Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study. J Pathol Transl Med 49(3):236–242

    Google Scholar 

  • Colby TV, Koss M, Travis W (1995) Tumors of the lower respiratory tract. atlas of tumor pathology, Third Series, Fascicle 13. Armed Forces Institute of Pathology, Washington, DC

    Google Scholar 

  • Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V et al (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29(8):1853–1860

    Google Scholar 

  • den Bakker MA, Willemsen S, Grunberg K, Noorduijn LA, van Oosterhout MF, van Suylen RJ et al (2010) Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology 56(3):356–363

    Google Scholar 

  • Eguchi T, Kadota K, Park BJ, Travis WD, Jones DR, Adusumilli PS (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26(3):210–222

    Google Scholar 

  • Emoto K, Eguchi T, Tan KS, Takahashi Y, Aly RG, Rekhtman N et al (2019) Expansion of the concept of micropapillary adenocarcinoma to include a newly recognized filigree pattern as well as the classical pattern based on 1468 stage I lung adenocarcinomas. J Thorac Oncol 14(11):1948–1961

    Google Scholar 

  • Evrard SM, Taranchon-Clermont E, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos YC et al (2019) Multicenter evaluation of the fully automated PCR-based Idylla EGFR mutation assay on formalin-fixed, paraffin-embedded tissue of human lung cancer. J Mol Diagn 21(6):1010–1024

    Google Scholar 

  • Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T et al (2015) High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta Panel: exploring therapeutic targets. Ann Oncol 26(8):1748–1753

    Google Scholar 

  • Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D et al (2014) Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 5:3518

    Google Scholar 

  • French CA (2012) Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 7:247–265

    Google Scholar 

  • Funai K, Yokose T, Ishii G, Araki K, Yoshida J, Nishimura M et al (2003) Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 27(7):978–984

    Google Scholar 

  • Geles A, Gruber-Moesenbacher U, Quehenberger F, Manzl C, Al Effah M, Grygar E et al (2015) Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. Virchows Arch 467(6):675–686

    Google Scholar 

  • George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G et al (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524(7563):47–53

    Google Scholar 

  • Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N et al (2014) Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42–e50

    Google Scholar 

  • Hwang I, Park KU, Kwon KY (2014) Modified histologic classification as a prognostic factor in pulmonary adenocarcinoma. Int J Surg Pathol 22(3):212–220

    Google Scholar 

  • Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J et al (2007) Nonsmall cell lung carcinoma with neuroendocrine differentiation—an entity of no clinical or prognostic significance. Am J Surg Pathol 31(1):26–32

    Google Scholar 

  • Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW et al (2014) Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 9(8):1126–1139

    Google Scholar 

  • Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB et al (2018) Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 36(9):911–919

    Google Scholar 

  • Kaufmann O, Dietel M (2000) Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 36(5):415–420

    Google Scholar 

  • Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H et al (2020) Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl Immunohistochem Mol Morphol 28(3):237–242

    Google Scholar 

  • Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B et al (2017) MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer 106:131–137

    Google Scholar 

  • Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K et al (2010) Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol 11(6):618–626

    Google Scholar 

  • Lee G, Lee HY, Jeong JY, Han J, Cha MJ, Lee KS et al (2015) Clinical impact of minimal micropapillary pattern in invasive lung adenocarcinoma: prognostic significance and survival outcomes. Am J Surg Pathol 39(5):660–666

    Google Scholar 

  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8(7):823–859

    Google Scholar 

  • Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 13(3):323–358

    Google Scholar 

  • Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J et al (2016) Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol 34(8):794–802

    Google Scholar 

  • Lococo F, Torricelli F, Rossi G, Alifano M, Damotte D, Rapicetta C et al (2017) Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. Lung Cancer 113:93–101

    Google Scholar 

  • Marchevsky AM, Walts AE (2015) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). Semin Diagn Pathol 32(6):438–444

    Google Scholar 

  • Marchevsky AM, Gal AA, Shah S, Koss MN (2001) Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 116(4):466–472

    Google Scholar 

  • Marchio C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G et al (2017) Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch 471(6):713–720

    Google Scholar 

  • Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA et al (2007) Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 84(3):973–980

    Google Scholar 

  • Matoso A, Singh K, Jacob R, Greaves WO, Tavares R, Noble L et al (2010) Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 18(2):142–149

    Google Scholar 

  • Mino-Kenudson M (2020) Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective. Transl Lung Cancer Res 9(3):847–859

    Google Scholar 

  • Moreira AL, Joubert P, Downey RJ, Rekhtman N (2014) Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma. Hum Pathol 45(2):213–220

    Google Scholar 

  • Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y et al (2020) A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 15(10):1599–1610

    Google Scholar 

  • Moro D, Brichon PY, Brambilla E, Veale D, Labat F, Brambilla C (1994) Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 73(11):2734–2739

    Google Scholar 

  • Moro-Sibilot D, Lantuejoul S, Diab S, Moulai N, Aubert A, Timsit JF et al (2008) Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 31(4):854–859

    Google Scholar 

  • Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF (2019) Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol 32(1):100–109

    Google Scholar 

  • Nakanishi K, Sakakura N, Matsui T, Ueno H, Nakada T, Oya Y et al (2019) Clinicopathological features, surgical outcomes, oncogenic status and PD-L1 expression of pulmonary pleomorphic carcinoma. Anticancer Res 39(10):5789–5795

    Google Scholar 

  • NCCN (2021a) National Comprehensive Cancer Network guidelines. NCCN, Philadelphia

    Google Scholar 

  • NCCN (2021b) National Comprehensive Cancer Network guidelines V. 2.2021

    Google Scholar 

  • Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC et al (2018) Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung. J Thorac Oncol 13(2):205–217

    Google Scholar 

  • Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S et al (2012) Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol 7:3

    Google Scholar 

  • Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E et al (1999) Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85(3):600–607

    Google Scholar 

  • Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y et al (2014) Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest 145(3):473–479

    Google Scholar 

  • Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES et al (2012) Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825–832

    Google Scholar 

  • Pelosi G, Rodriguez J, Viale G, Rosai J (2005) Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 29(2):179–187

    Google Scholar 

  • Pelosi G, Rindi G, Travis WD, Papotti M (2014) Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 9(3):273–284

    Google Scholar 

  • Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE et al (2019) Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. J Thorac Oncol 14(3):482–493

    Google Scholar 

  • Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL et al (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18(4):1167–1176

    Google Scholar 

  • Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H et al (2016) Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22(14):3618–3629

    Google Scholar 

  • Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R et al (2017) Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. J Thorac Oncol 12(6):932–942

    Google Scholar 

  • Shang X, Li Z, Sun J, Zhao C, Lin J, Wang H (2021) Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer 154:105–112

    Google Scholar 

  • Shih AR, Mino-Kenudson M (2020) Updates on spread through air spaces (STAS) in lung cancer. Histopathology 77(2):173–180

    Google Scholar 

  • Shih AR, Uruga H, Bozkurtlar E, Chung JH, Hariri LP, Minami Y et al (2019) Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. Histopathology 75(5):649–659

    Google Scholar 

  • Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F et al (2021) STK1/LKB1 mutations in NSCLC are associated with KEAP1/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition. Clin Cancer Res 27(6):1720–1733

    Google Scholar 

  • Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF et al (2018) STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8(7):822–835

    Google Scholar 

  • Sobin L, Gospodarowicz M, Wittekind C (eds) (2017) TNM classification malignant tumours, 8th edn. Wiley-Blackwell, Oxford

    Google Scholar 

  • Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 455(2):125–132

    Google Scholar 

  • Suster DI, Mino-Kenudson M (2020) Molecular pathology of primary non-small cell lung cancer. Arch Med Res 51(8):784–798

    Google Scholar 

  • Swarts DR, Rudelius M, Claessen SM, Cleutjens JP, Seidl S, Volante M et al (2017) Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. Histopathology 70(3):412–422

    Google Scholar 

  • Terra SB, Jang JS, Bi L, Kipp BR, Jen J, Yi ES et al (2016) Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol 29(8):824–831

    Google Scholar 

  • Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S et al (2012) Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 25(12):1574–1583

    Google Scholar 

  • Thunnissen E, Noguchi M, Aisner S, Beasley MB, Brambilla E, Chirieac LR et al (2014) Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol 9(9):1354–1362

    Google Scholar 

  • Travis WD, Muller-Hermelink HK, Harris CC, Hammar SP, Brambilla C, Pugatch B (2004) WHO tumours pathology and genetics of tumours of the lung, pleura, thymus and heart, 3rd edn. IARC Press, Lyon, France

    Google Scholar 

  • Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285

    Google Scholar 

  • Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart, 4th edn. IARC Press, Lyon, France

    Google Scholar 

  • Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB et al (2016) The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 11(8):1204–1223

    Google Scholar 

  • Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L et al (2020) IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol 15(5):709–740

    Google Scholar 

  • Travis WD, Dacic S, Sholl LM, Wistuba II (2021) Pathologic assessment of lung squamous cell carcinoma after neoadjuvant immunotherapy. J Thorac Oncol 16(1):e9–e10

    Google Scholar 

  • Tsutani Y, Miyata Y, Mimae T, Kushitani K, Takeshima Y, Yoshimura M et al (2013) The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. J Thorac Cardiovasc Surg 146(3):580–585

    Google Scholar 

  • Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M et al (2015) Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type? Oncotarget 6(27):23905–23916

    Google Scholar 

  • Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y et al (2014) Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol 9(6):760–768

    Google Scholar 

  • Warth A, Muley T, Harms A, Hoffmann H, Dienemann H, Schirmacher P et al (2016) Clinical relevance of different papillary growth patterns of pulmonary adenocarcinoma. Am J Surg Pathol 40(6):818–826

    Google Scholar 

  • Weichert W, Schewe C, Denkert C, Morawietz L, Dietel M, Petersen I (2009) Molecular HPV typing as a diagnostic tool to discriminate primary from metastatic squamous cell carcinoma of the lung. Am J Surg Pathol 33(4):513–520

    Google Scholar 

  • Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA et al (2020) Agreement on major pathological response in NSCLC patients receiving neoadjuvant chemotherapy. Clin Lung Cancer 21(4):341–348

    Google Scholar 

  • Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T et al (2021) Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer 154:76–83

    Google Scholar 

  • WHO Classification of Tumours Editorial Board (2021) Thoracic tumours, WHO classification of tumours series, vol 5, 5th edn. IARC Press, Lyon, France

    Google Scholar 

  • William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II et al (2013) Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8(2):222–228

    Google Scholar 

  • Yanagawa N, Wang A, Kohler D, Santos Gda C, Sykes J, Xu J et al (2013) Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. Lung Cancer 79(3):215–220

    Google Scholar 

  • Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S et al (2019) Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol 14(3):377–407

    Google Scholar 

  • Yatabe Y, Borczuk A, Cooper W, Dacic S, Kerr K, Moreira A et al (eds) (2020) IASLC atlas of diagnostic immunohistochemistry. IASLC, Denver, CO

    Google Scholar 

  • Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A et al (2012) Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery 152(3):397–402

    Google Scholar 

  • Zens P, Bello C, Scherz A, Koenigsdorf J, Pollinger A, Schmid RA et al (2021) A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. Mod Pathol 34:1333–1344

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary Pathology Service, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Mari Mino-Kenudson

Authors
  1. Mari Mino-Kenudson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mari Mino-Kenudson .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mino-Kenudson, M. (2022). Pathology of Lung Cancer. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_301

Download citation

  • DOI: https://doi.org/10.1007/174_2022_301

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation